Skip to main content
CAI logo

CAI · Caris Life Sciences, Inc.

Track CAI — free
$18.54 -0.96 (-4.92%)
Market Cap
$5.32B
Shares
286.78M
Volume · Nov 19 3.6M Avg daily vol (3M) 4.66M

Price & Indicators

Close$18.54 Open$19.86 Day$18.52–20.82 52W close$14.55–36.14 Avg vol 30d4.0M Short int11.5M · 4.0% of shares · 4.0d Short vol47% Last earningsNov 4, 2026 DataJun 2025–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Earnings call
Revenue rises 27% as full-year outlook is raised

Caris Life Sciences, Inc. reported third-quarter revenue of $275.4 million, up 27% year-over-year, with adjusted EBITDA of $44.4 million and GAAP net income of $15.3 million. Management raised full-year revenue guidance to $1.04 billion to $1.05 billion.

Read from the first part of this long document
4 source passages
We delivered another strong quarter with total revenue of $275.4 million, which is up 27% year-over-year, and brings our nine-month revenue to $755.2 million, which is up 45% year-to-date. Adjusted EBITDA was $44.4 million, our sixth consecutive positive quarter, compared with $51.2 million in the prior year, which again carried a larger true-up benefit. Year-to-date, adjusted EBITDA is $126.3 million, up from $31.7 million for the same nine months last year. These results produced GAAP net income of $15.3 million compared with $24.3 million a year ago. Finally, turning to guidance, given the strength of our first nine months, we're raising our full-year outlook range to approximately $1.04 billion to $1.05 billion, up from $1.03 to $1.04 billion, representing growth of approximately 28 to 29 percent, driven by molecular profiling Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 45.5%; net income reaches $14.1 million

Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.

Revenue $275.36M ▲ 27.0% Net income $15.25M ▼ 37.3% Diluted EPS $0.05 ▼ 37.5%
Read from the MD&A section
4 source passages
Total revenue was $755.2 million for the nine months ended September 30, 2026, compared to $519.1 million for the nine months ended September 30, 2025, an increase of $236.1 million, or 45.5%. For the nine months ended September 30, 2026 and 2025, we generated total revenue of $755.2 million and $519.1 million, respectively, and reported net income (loss) of $14.1 million and $(150.0) million, respectively. Total revenue was $275.4 million for the three months ended September 30, 2026, compared to $216.8 million for the three months ended September 30, 2025, an increase of $58.5 million, or 27.0%. For the three months ended September 30, 2026 and 2025, we generated total revenue of $275.4 million and $216.8 million, respectively, and reported net income of $15.3 million and $24.3 million, respectively. Open the document at this passage
Nov 4
Current report 8-K
Revenue up 27%, full-year 2026 guidance raised

Caris Life Sciences reported results for the quarter ended September 30, 2026: total revenue of $275.4 million, up 27%, and net income of $15.3 million. Full-year 2026 revenue guidance raised to $1.04 to $1.05 billion, growth of 28% to 29%.

Financial results
4 source passages
Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period. Reported net income of $15.3 million. Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.05B
Trailing 12 months
Net income (TTM)
$96.06M
Trailing 12 months
Revenue growth YoY
+27.0%
Year over year
Operating margin
13.4%
Trailing 12 months
P / E (TTM)
2.4
Trailing earnings · reciprocal yield 42.5%
FCF yield
—
TTM · current market cap
Return on invested capital
90.1%
Trailing 12 months
Net cash
$440.64M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-17.9%
Trailing year
Short interest
4.0%
Latest settlement · 4.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Revenue rose 27%, clinical cases rose 21%, and 2026 guidance increased to $1.04 to $1.05 billion; Caris also remained profitable and launched monitoring ahead of a targeted MRD launch. Gross margin contracted, net income and adjusted EBITDA were below prior-year levels, operating expenses increased, free cash flow was negative, and FDA approval is not near term for Caris Detect.

Bullish
  • + Full-year 2026 revenue guidance was raised to $1.04 to $1.05 billion, representing 28% to 29% growth.
  • + Third-quarter revenue increased 27% year over year to $275.4 million.
  • + Clinical case volume increased approximately 21% year over year to approximately 61,500 cases.
  • + Caris generated $44.4 million of adjusted EBITDA and returned to GAAP profitability with $15.3 million of net income.
  • + Caris launched therapy-response monitoring and targeted Caris Confirm for launch before year-end.
  • + The preliminary 2027 clinical lab fee schedule increased the Caris Assure rate to $5,250 from $3,650.
Bearish
  • − Gross margin declined to 66% from 68% in the prior-year quarter.
  • − GAAP net income declined to $15.3 million from $24.3 million in the prior-year quarter.
  • − Operating expenses increased 42% year over year to $163.0 million.
  • − Third-quarter free cash flow was negative $39.7 million.
  • − Third-quarter adjusted EBITDA declined to $44.4 million from $51.2 million in the prior-year quarter.
  • − An FDA pathway for Caris Detect is not in the near-term future.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −36%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 18%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −42%
trailing
6-month return +13%
trailing
YTD return −31%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +125 funds added
Insider flow Distributing
Net -$27.2M over 90 days · 100% sells
Short interest Falling
4.01% of shares out · ▼ -15.4% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
334 holders — near 1-yr high, broad support
Squeeze score 46
elevated · 0–100
Fundamentals
Excellent
Revenue growth +97%
Y/Y
EPS growth +70%
Y/Y
Free cash flow $66.9M
Valuation P/E 55.4
in line
Buyback $72.1M
remaining
Balance sheet $417.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −50%
past year
ATR 11.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 4, 2026
Total revenue · full year 2026 Raised $1.04B – $1.05B
Aug 5, 2026 $1.03B – $1.04B changed to Nov 4, 2026 $1.04B – $1.05B
prior FY $812.03M midpoint +28.7% Y/Y
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Total revenue growth · full year 27% – 28%
EBITDA · Q3 $10M – $60M
Gross margin · second half of the year 60%
Volume growth · Q3 20%
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
CapEx · Q3 $15M – $20M
Guided vs delivered · last 1 settled
Revenue full year 2025
guided $720M – $730M
$812.03M Beat +12.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−36% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
18% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $29 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +125 funds added
Insider flow Distributing
Net -$27.2M over 90 days · 100% sells
Short interest Falling
4.01% of shares out · ▼ -15.4% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
334 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $19 · 18% Range high $36
vs 200-day avg -14% vs 50-day avg -36%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $55.7M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net loss -637K
-6.82M Interest income
+9.23M Interest expense
+0K Changes in fair value of financial instruments
+25.13M Other expense, net
+23K Income tax expense (benefit)
+6.54M Depreciation and amortization expense
+22.22M Stock-based compensation expense
= Adjusted EBITDA 55.68M
Caris Assure cases 10,700 Q2 2026 —
Free cash flow non-GAAP $6.4M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by (used in) operating activities 28.48M
-22.08M Less: capitalized software and purchases of property and equipment
= Free cash flow 6.4M
MI Profile cases 48,300 Q2 2026 —
Revenue from clinical cases for patients covered by Medicare 38.9% the three months ended June 30, 2026 filing —
Share repurchase program (remaining authorization) $82.1M as of August 5, 2026 —
Total matched profiles 845,000 through June 30, 2026 —
Total oncology tests 345,000 Q2 2026 —
Total profiles 1,130,000 through June 30, 2026 —
Whole exome profiles 733,000 through June 30, 2026 —
Whole exome/whole transcriptome tests 114,000 Q2 2026 —
Whole transcriptome profiles 783,000 through June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CAI
Caris Life Sciences, Inc.
this stock
$5.32B -31.3% +97.0% 55.4 4.0%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
334
% held
54.1%
Net QoQ
+689.2K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
231
View
Short & Settlement
Short Interest Falling
Shares short
11.5M
Days to cover
4.0d
Change
-2.1M sh
View
Short Volume
Short vol %
47%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
166.6K
Value
$5.2M
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
44.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$27.2M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$812.0M
Net income (FY)
$-68.1M
EPS diluted
$-3.22
View
Buybacks
Authorized
$100.0M
Remaining
$72.1M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
18

Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.

View
Proposed Sales
Value
$238.6K
Shares
7.5K
Filed
Sep 22, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Caris Life Sciences Reports Third…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
CAI -22.6% -41.5% +12.7% -46.0% -31.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -17.2% -35.2% +18.3% -40.7% -36.3%

Capital returns

Buyback program · as of Nov 4, 2026
Authorized
$100.00M
Spent (derived)
$27.90M
Remaining
$72.10M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 2019410 CUSIP 142152107 13F (30d) 330 filings 313 filers Visit website Investor relations